Clinical Trials · NCT06161844
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 506
- Start date
- Feb 2024
- Locations
- 1 site, China
- Primary endpoint
- Change from baseline to week 32 in glycosylated haemoglobin (HbA1c)